These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 33853586)
21. Detection of Potential Mutated Genes Associated with Common Immunotherapy Biomarkers in Non-Small-Cell Lung Cancer Patients. Cao L; Cao Z; Liu H; Liang N; Bing Z; Tian C; Li S Curr Oncol; 2022 Aug; 29(8):5715-5730. PubMed ID: 36005189 [TBL] [Abstract][Full Text] [Related]
22. Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients. Duffy MJ; Crown J Clin Chem; 2019 Oct; 65(10):1228-1238. PubMed ID: 31315901 [TBL] [Abstract][Full Text] [Related]
23. Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers. Nazha B; Zhuang T; Wu S; Brown JT; Magee D; Carthon BC; Kucuk O; Nabhan C; Barata PC; Heath EI; Ryan CJ; McKay RR; Master VA; Bilen MA Cancer; 2023 Dec; 129(24):3884-3893. PubMed ID: 37565840 [TBL] [Abstract][Full Text] [Related]
24. Expression Profile of Markers for Targeted Therapy in Gastric Cancer Patients: HER-2, Microsatellite Instability and PD-L1. Pereira MA; Ramos MFKP; Dias AR; Faraj SF; Ribeiro RRE; de Castria TB; Zilberstein B; Alves VAF; Ribeiro U; de Mello ES Mol Diagn Ther; 2019 Dec; 23(6):761-771. PubMed ID: 31595457 [TBL] [Abstract][Full Text] [Related]
25. Comprehensive Genomic Profiling of Rare Tumors in China: Routes to Immunotherapy. Wang S; Fang Y; Jiang N; Xing S; Li Q; Chen R; Yi X; Zhang Z; Li N Front Immunol; 2021; 12():631483. PubMed ID: 33732253 [TBL] [Abstract][Full Text] [Related]
26. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers. Palmeri M; Mehnert J; Silk AW; Jabbour SK; Ganesan S; Popli P; Riedlinger G; Stephenson R; de Meritens AB; Leiser A; Mayer T; Chan N; Spencer K; Girda E; Malhotra J; Chan T; Subbiah V; Groisberg R ESMO Open; 2022 Feb; 7(1):100336. PubMed ID: 34953399 [TBL] [Abstract][Full Text] [Related]
27. Molecular characteristics of early-onset compared with late-onset colorectal cancer: a case controlled study. Tang J; Peng W; Tian C; Zhang Y; Ji D; Wang L; Jin K; Wang F; Shao Y; Wang X; Sun Y Int J Surg; 2024 Aug; 110(8):4559-4570. PubMed ID: 38742845 [TBL] [Abstract][Full Text] [Related]
28. Biomarkers and computational models for predicting efficacy to tumor ICI immunotherapy. Qin Y; Huo M; Liu X; Li SC Front Immunol; 2024; 15():1368749. PubMed ID: 38524135 [TBL] [Abstract][Full Text] [Related]
29. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. Sabari JK; Leonardi GC; Shu CA; Umeton R; Montecalvo J; Ni A; Chen R; Dienstag J; Mrad C; Bergagnini I; Lai WV; Offin M; Arbour KC; Plodkowski AJ; Halpenny DF; Paik PK; Li BT; Riely GJ; Kris MG; Rudin CM; Sholl LM; Nishino M; Hellmann MD; Rekhtman N; Awad MM; Drilon A Ann Oncol; 2018 Oct; 29(10):2085-2091. PubMed ID: 30165371 [TBL] [Abstract][Full Text] [Related]
30. Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing. Kim HS; Cha H; Kim J; Park WY; Choi YL; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH Eur J Cancer; 2019 Oct; 120():65-74. PubMed ID: 31493723 [TBL] [Abstract][Full Text] [Related]
31. The predictive value of next generation sequencing for matching advanced hepatocellular carcinoma patients to targeted and immunotherapy. Du J; Zhang E; Huang Z Front Immunol; 2024; 15():1358306. PubMed ID: 38665910 [TBL] [Abstract][Full Text] [Related]
32. Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer. Huang D; Zhang F; Tao H; Zhang S; Ma J; Wang J; Liu Z; Cui P; Chen S; Huang Z; Wu Z; Zhao L; Hu Y Target Oncol; 2020 Feb; 15(1):93-100. PubMed ID: 32052340 [TBL] [Abstract][Full Text] [Related]
33. PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer. Chen Y; Liu Q; Chen Z; Wang Y; Yang W; Hu Y; Han W; Zeng H; Ma H; Dai J; Zhang H J Exp Clin Cancer Res; 2019 May; 38(1):193. PubMed ID: 31088500 [TBL] [Abstract][Full Text] [Related]
34. [Detection and Significance of Molecular Markers in Immunotherapy and Targeted Therapy of Colorectal Cancer in Tibet]. Luo HH; Liu BY; Huo Z; BIANbazhaxi ; Wang Q; DUObula ; NImazhuoma ; DA Z; Wang H; Guo PP Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2024 Apr; 46(2):184-192. PubMed ID: 38686714 [TBL] [Abstract][Full Text] [Related]
35. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair. Ratovomanana T; Cohen R; Svrcek M; Renaud F; Cervera P; Siret A; Letourneur Q; Buhard O; Bourgoin P; Guillerm E; Dorard C; Nicolle R; Ayadi M; Touat M; Bielle F; Sanson M; Le Rouzic P; Buisine MP; Piessen G; Collura A; Fléjou JF; de Reyniès A; Coulet F; Ghiringhelli F; André T; Jonchère V; Duval A Gastroenterology; 2021 Sep; 161(3):814-826.e7. PubMed ID: 33992635 [TBL] [Abstract][Full Text] [Related]
36. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1. Liu J; Liu Y Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773 [TBL] [Abstract][Full Text] [Related]
37. Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy. Aggarwal C; Ben-Shachar R; Gao Y; Hyun SW; Rivers Z; Epstein C; Kaneva K; Sangli C; Nimeiri H; Patel J JAMA Netw Open; 2023 May; 6(5):e2311181. PubMed ID: 37129893 [TBL] [Abstract][Full Text] [Related]
38. Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy. Zhou KI; Peterson B; Serritella A; Thomas J; Reizine N; Moya S; Tan C; Wang Y; Catenacci DVT Clin Cancer Res; 2020 Dec; 26(24):6453-6463. PubMed ID: 32820017 [TBL] [Abstract][Full Text] [Related]
39. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study. Antoniotti C; Korn WM; Marmorino F; Rossini D; Lonardi S; Masi G; Randon G; Conca V; Boccaccino A; Tomasello G; Passardi A; Swensen J; Ugolini C; Oberley M; Tamburini E; Casagrande M; Domenyuk V; Fontanini G; Giordano M; Abraham J; Spetzler D; Falcone A; Lenz HJ; Cremolini C Eur J Cancer; 2021 Sep; 155():73-84. PubMed ID: 34365081 [TBL] [Abstract][Full Text] [Related]
40. Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer. Sivapiragasam A; Ashok Kumar P; Sokol ES; Albacker LA; Killian JK; Ramkissoon SH; Huang RSP; Severson EA; Brown CA; Danziger N; McGregor K; Ross JS Cancer Med; 2021 Jan; 10(1):53-61. PubMed ID: 33314633 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]